title: CA-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis.
abstract: BACKGROUND
  Most malignancies with peritoneal infiltration, especially ovarian cancers and chronic liver diseases associated with ascites give rise to high serum CA-125 levels. Tuberculous peritonitis is another cause for high serum CA-125 levels.
  
  
  OBJECTIVE
  To investigate the relation between serum CA-125 level and response to treatment in tuberculous peritonitis patients.
  
  
  METHODS
  Ten patients with tuberculous peritonitis were enrolled in the study.
  
  
  METHODS
  Definite diagnosis of tuberculous peritonitis was made by acid-fast smears, specific culture, and polymerase chain reaction. Serum CA-125 levels were measured before and at the fourth month of treatment.
  
  
  RESULTS
  Before antituberculous treatment, serum CA-125 levels of all patients were very high (mean+/-SD: 475. 80+/-106. 19 U/ml) and comparable with those of patients with ovarian cancers. At the end of the fourth month of treatment, serum CA-125 levels in all patients decreased to within normal limits (<35 U/ml)(20.80:+/-5.18 U/ml) in parallel with the clinical improvement. The differences in CA125 levels before and after treatment were statistically significant (p<0.001).
  
  
  CONCLUSIONS
  Results of our study suggest that serum CA-125 levels in patients with tuberculous peritonitis are as high as ovarian cancers associated with peritoneal infiltration. By the end of the fourth month of antituberculous therapy, serum CA-125 levels have returned to normal. We, therefore, suggest that serum CA-125 can be used to evaluate the efficacy of therapy in tuberculous peritonitis.
authors.affiliation: Department of Internal Medicine, Gülhane School of Medicine, Etlik, Ankara, Turkey. refikmas@yahoo.com
authors.forename: M R
authors.initials: MR
authors.lastname: Mas
authors.forename: B
authors.initials: B
authors.lastname: Cömert
authors.forename: U
authors.initials: U
authors.lastname: Sağlamkaya
authors.forename: L
authors.initials: L
authors.lastname: Yamanel
authors.forename: O
authors.initials: O
authors.lastname: Kuzhan
authors.forename: U
authors.initials: U
authors.lastname: Ateşkan
authors.forename: F
authors.initials: F
authors.lastname: Kocabalkan
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications; D010538:Peritonitis / Q000209:etiology / Q000276:immunology; D014395:Peritonitis, Tuberculous / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*
chemical_list: D000995:Antitubercular Agents; D015415:Biomarkers; D018394:CA-125 Antigen